Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559338 | 0.84 | MAPK1 (0.35) | GPR35ALDH1A1TDP1 | |
| SCHEMBL12559202 | 0.80 | SMN1; SMN2 (0.42) | ALDH1A1TDP1PKM | |
| SCHEMBL11468226 | 0.78 | TDP1 (0.39) | ALDH1A1TDP1PKM | |
| SCHEMBL3744691 | 0.71 | CYP1A2 (0.33) | ALDH1A1CYP1A2 | |
| SCHEMBL12559340 | 0.71 | TDP1 (0.39) | GPR35ALDH1A1CYP1A2TDP1 | |
| SCHEMBL12559229 | 0.68 | GSK3B (0.31) | CYP1A2 | |
| SCHEMBL12559242 | 0.68 | GPR35 (0.39) | GPR35CYP1A2TDP1 | |
| SCHEMBL12559204 | 0.68 | PTPN1 (0.33) | — | |
| SCHEMBL1475958 | 0.67 | CA1 (0.42) | GPR35ALDH1A1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL7747923 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010011748-A2 | SYNTHETIC INTERMEDIATES AND PROCESSES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144321-A1 | SYNTHETIC INTERMEDIATES AND PROCESSES | G6PD, GALE, UGGT1 | GPR35 3546/4885ALDH1A1 1126/4885CYP1A2 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.